MSMorteza Saeidi

Morteza Saeidi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Morteza Saeidi has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Prospective to Regulatory Role of miRNAs on Wnt/β-catenin Signaling and Its Crosstalk to the Other Cellular Pathways in Tumorigenesis of Glioblastoma by a Systems Biology Approach

    by Morteza Saeidi, Alireza Pasdar, Farzad Rahmani, Abozar Ghorbani, Negar Mottaghi, Forouzan Amerizadeh

    Background: The Wnt plays a crucial role in the initiation, progression, and spread of glioblastoma (GBM). Recently, microRNAs (miRNAs) have been demonstrated to be key players in controlling cell growth and tumor formation. Objectives: The present study offers the latest insight into miRNAs that influence the Wnt pathway and their interaction with protein-coding genes. Methods: Previous studies on the regulatory function of miRNAs targeting the Wnt/catenin pathway were reviewed, and all miRNA-targeted genes were found in the miRDB database. Protein-protein interactions (PPIs) of miRNA-targeted genes were investigated using String and Cytoscape software, and hub proteins were examined. Gene-subnetwork Gene Ontology (GO) analysis was performed. Results: At first, 13 downregulated and 25 upregulated miRNAs targeting the Wnt pathway were obtained, each targeting 1,685 and 1,313 genes, respectively; 12 and 15 hub proteins were found in dysregulated miRNA-targeted genes, which interacted with most genes. The PPI network analysis and subnetwork GO analysis showed these proteins cross-talk with many other proteins that have key roles in the pathways that cause proliferation and malignancy in cells. Conclusions: Hub proteins are oncogenic proteins that increase gene replication and suppress apoptotic pathways, or tumor suppressors that prevent cancer. By focusing on hub proteins alone or as part of a multi-target approach, it is possible to treat GBM tumors successfully.


  • Open Access

    Evaluation of Ocrelizumab (Xacrel) on Walking Ability in Multiple Sclerosis Patients: A First Report From Iran

    by Mahshid Mahyad, Morteza Saeidi, Kosar Kohandel, Maryam Ebrahimian, Mahdieh Baghaei, Shima Jahani, Mohammadali Nahayati

    Introduction: Ocrelizumab (OCR) and rituximab (RTX) are monoclonal antibodies targeting CD20 on B cells, a promising approach for relapsing–remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS). They aim to modulate the immune system and reduce B cells, potentially leading to fewer relapses and delayed disease progression. Xacrel, the Iranian‐made OCR biosimilar, requires further investigation for its effectiveness in MS treatment. The Timed 25‐Foot Walk (T25FW) has been one of the key implements for assessing mobility in MS patients for over two decades, and recent studies confirmed that comprehensive treatment—especially with fampridine and OCR—significantly improves T25FW performance. Objective: We aim to assess the effectiveness of Xacrel (Iranian OCR) for MS treatment by evaluating alteration in Expanded Disability Status Scale (EDSS) score and T25FW test. This study also explores the potential benefits of switching patients’ drug from RTX to OCR. Material and Methods: This prospective cohort study at Qaem Hospital (February 2022–May 2024) on 143 MS patients evaluates Xacrel in MS patients using EDSS and T25FW scores before treatment and at 6 and 12 months posttreatment. Additionally, we assessed 29 MS patients whose drug transitioned from RTX to OCR to compare the effectiveness of these treatments. For this purpose, MS progression was assessed using the EDSS score and T25FW test at baseline, 6 months, and 12 months after switching their medication. Results: In our study, the average age was 38.48 ± 8.73 years, and over 70% were women. 76.2% were between 30–50 years old, with a mean disease duration of 6 years. About 19.6% were treatment‐naive, with dimethyl fumarate as the most common first‐line drug. Over 12 months, significant declines in EDSS scores and increases in T25FW tests were noted at 6 and 12 months compared to baseline (all p < 0.05), but not between 6 and 12 months. Significant factors were RRMS for 6‐month EDSS score changes ( p = 0.011) and treatment‐naive patients for T25FW at 6 months ( p = 0.018) and 12 months ( p = 0.004). Switching from RTX to OCR showed no significant changes in EDSS or T25FW scores, despite trends of decreases in EDSS and increases in T25FW times at 6 and 12 months. Subgroup analyses by gender, age, disease duration, type, and previous medication history showed no significant differences. Conclusion: In MS patients—particularly treatment‐naive individuals and those with RRMS—Xacrel (an Iranian‐produced biosimilar of OCR) effectively inhibited EDSS progression, significantly reduced EDSS scores, and enhanced T25FW performance. In contrast, switching from RTX to Xacrel did not result in significant changes in mobility outcomes or disability status.

  • Open Access

    Efficacy and safety of Vicia faba L. extract compared with levodopa in management of Parkinson’s disease and an in‐silico phytomedicine analysis

    by Karim Nikkhah, Ali Shoeibi, Fariborz Rezaeitalab, Samira Aminzadeh, Hussein Sharara, Mahdi Abbas-Mohammadi, Mohammad Al-Attar, Mohammadeza Akbari, Fereydun Moradi, Hasan Rakhshandeh, et al.

    Background: Parkinson’s disease is a chronic degenerative disease of the central nervous system, presently lacks an effective therapy for its complex pathogenesis. Agents containing Levodopa can alleviate its symptoms. Hypothesis Vicia faba L. (Fava bean) extract may prove a useful antiparkinsonian agent similar to Levodopa. Methods: Thirty patients with Parkinson’s disease, entered into this cross over clinical study. In the first step, each participant received V. faba L. extract containing 106.5 mg of Levodopa. After a wash out period of 7 days, the patients entered the second step during which they received conventional treatment with Levodopa-C tablets. Blood Levodopa were measured 4 hours and 8 hours after each administration. The Movement Disorder Society-Unified Parkinson’s Disease Rating Scale was employed to measure the therapeutic effects in each step. Additionally, a docking analysis was performed to distinguish the chemical constituents of the plant and six key mediators actively involved in Parkinson disease. Results: The fava bean extract significantly alleviate all studied end points except for tremor at rest and freezing. Wilcoxon Signed Ranks Test showed that there was not a significant difference between rigidity, rising chair, gait and bradykinesia. Docking results of the herb components and standard ligands, indicating that the antiparkinsonian activity of V. faba could presumably be related to many phytochemicals. Conclusion: This study showed a beneficial effect of V. faba L. similar to Levodopa-C. and better compliance due to lower adverse events.


  • Open Access

    Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis

    by Fatemeh Yavari, Pardis Oliazadeh, Meisam Radfar, Mohsen Foroughipour, Karim Nikkhah, Alireza Heidari Bakavoli, Morteza Saeidi

    Introduction: Fingolimod is the first confirmed oral immune-modulator to treat Relapsing-Remitting Multiple Sclerosis (RRMS). This study aimed to investigate the safety and efficacy of fingolimod therapy in Iranian patients with RRMS. Methods: In our trial, 50 patients resistant to conventional interferon therapy were assigned to receive fingolimod 0.5 mg per day for 12 months. The number of Dadolinium (Gd)-enhanced lesions, enlarged T2 lesions, and relapses over 12 months were considered as endpoints and compared to baseline. Liver biochemical evaluations and lymphocyte count were done at baseline and in months 3, 6, and 12 of the study. Patients were also monitored for possible cardiovascular events within the first 24 h and other side effects routinely. Results: Among the patients who completed the trial, the number of Gd-enhanced and enlarged T2 lesions over 12 months significantly decreased (P=0.03 and P<0.001, respectively). The proportion of relapse-free patients was higher compared to the onset of fingolimod administration. There were no significant alterations in the Expanded Disability Status Scale (EDSS) scores. A slight, transient increase was recorded in liver enzymes among the participants. Lymphocyte count reduced by 61% at month 1 and displayed a gradual increase until month 12. No bradycardia and macular edema were recorded. Conclusion: These findings indicate an effective first-line fingolimod therapy for the first time in Iranian patients with RRMS. The decrease in the number of new attacks and the amelioration of MRI lesions were the benefits of fingolimod therapy, suggesting that it is preferred to other medicines to treat RRMS in Iran.


  • Open Access

    Demyelinating Changes Alike to Multiple Sclerosis: A Case Report of Rare Manifestations of COVID-19

    by Fatemeh Yavari, Sara Raji, Fatemeh Moradi, Morteza Saeidi

    COVID-19, as a global concern and pivotal issue in the healthcare system, could have various presentations, leading to difficulty in diagnosis and management. Neuroinvasive potency, as claimed by preliminary studies, is a considerable pathogenesis. Serious neurological disorders like multiple sclerosis (MS) were out of the blue to be the first demonstration of COVID-19. This report highlights the representation of MS in a young woman, which resulted in a COVID-19 diagnosis.